Baird Financial Group
NKTR icon

Baird Financial Group’s Nektar Therapeutics NKTR Stock Holding History

Baird Financial Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-14,785
Closed -$4.04M – 1534
2019
Q3 		$4.04M Buy
+14,785
New +$5.42M 0.02% 569
2019
Q2 		– Sell
-6,653
Closed -$3.37M – 1547
2019
Q1 		$3.37M Buy
+6,653
New +$3.94M 0.02% 539
2018
Q4 		– Sell
-1,025
Closed -$873K – 1328
2018
Q3 		$873K Buy
1,025
+5
+0.5% +$4.27K 0.01% 887
2018
Q2 		$747K Buy
1,020
+378
+59% +$436K 0.01% 903
2018
Q1 		$1.02M Buy
+642
New +$827K 0.01% 818

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

Baird Financial Group's NKTR Position: Q4 2019 in Review

Baird Financial Group sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 14,785 shares — an estimated $4.04M sold.

Baird Financial Group first reported a position in NKTR in Q1 2018 and held it in 5 quarters. The position peaked at $4.04M in Q3 2019. 280 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

  • Baird Financial Group reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Baird Financial Group sold 14,785 Nektar Therapeutics shares in Q4 2019, an estimated $4.04M.
  • Baird Financial Group first reported a position in Nektar Therapeutics in Q1 2018 and held it in 5 quarters.
  • Baird Financial Group's Nektar Therapeutics position peaked at $4.04M in Q3 2019.
  • 280 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on Baird Financial Group's 13F filing for Q4 2019, filed 14 Feb 2020.